Navigation Links
Sarasota's Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimer's Disease Research

Third-Party Japanese Study Suggests Drug Improves Memory

SARASOTA, Fla., Dec. 14 /PRNewswire/ -- The Roskamp Institute today announced that its promising new drug application for the treatment of Alzheimer's disease has received positive validation from an independent human clinical study conducted at the Tokyo Medical University in Japan. The study, which suggests the drug, Nilvadipine, can prevent the onset of Alzheimer's disease in patients with memory problems, is detailed in the International Journal of Geriatric Psychiatry, a highly prestigious medical research journal.

The Japanese study was conducted over the course of a 20-month period, where a group of 15 amnestic mild cognitive impairment (MCI) patients with essential hypertension were divided into two groups. A group of eight participants were randomly allocated to take the drug, Nilvadipine, while the other seven remaining participants were designated to take the drug, Amlodipine.

The study found that the group treated with Nilvadipine had stabilized their decline in memory over the 20 months; whereas, the group treated with Amlodipine had continued to suffer loss of cognitive function, which was double that of the small decline in the Nilvadipine controlled group.

"Although the study was conducted with a small sample size, this third- party validation is extremely encouraging, as there appears to be a strong protective effect from developing Alzheimer's in memory-troubled patients who were given Nilvadipine," said Dr. Michael Mullan, director of the Roskamp Institute, who has been researching the drug for its use in Alzheimer's disease.

The Roskamp Institute, which owns the worldwide proprietary rights to use Nilvadipine for Alzheimer's disease, has been conducting its own human clinical study in partnership with the Trinity College Institute of Neuroscience in Dublin, Ireland, and has recently reported in March that the use of the drug in Alzheimer's patients is receiving positive safety reviews.

While the drug, Amlodipine, is one of the top drugs sold in the United States for the treatment of hypertension (high blood pressure), Nilvadipine, is currently not available in the U.S. However, the Roskamp Institute plans to introduce Nilvadipine to the U.S. Food and Drug Administration as a part of its phase II study early next year.

"As the authors of the Japan study propose, our Institute's researchers are planning to investigate whether the Japan study finding can be replicated in a larger participant study," said Dr. Fiona Crawford, associate director of the Roskamp Institute, who has been working alongside Dr. Mullan in researching Nilvadipine for its use in Alzheimer's disease. "As we continue to move forward in our studies, we are hopeful that we are well on our way to finding a drug that will be useful in slowing down or preventing this devastating disease."

In addition, the Roskamp Institute is looking for volunteers who have been diagnosed with Alzheimer's disease or Multiple Sclerosis to participate in Roskamp's ongoing research studies. If you or someone you know is interested in participating, please contact our Clinical Trials Division at (941) 256- 8018.

The Roskamp Institute is a not-for-profit research Institute located in Sarasota and Tampa, Florida, that is dedicated to understanding the causes of, and finding cures for, neuropsychiatric and neurodegenerative disorders and addictions with an emphasis on Alzheimer's disease. The Institute's Memory Clinics also offer comprehensive cognitive and medical assessment toward differential diagnosis of Alzheimer's disease and offers treatments and disease management options once the diagnostic evaluation is complete.

For more information, please contact the Roskamp Institute in Sarasota at (941) 752-2949, the Roskamp Institute Clinical Trials Division in Sarasota at (941) 256-8018 the Roskamp Institute Memory Center in Tampa at (813) 979-2008, or visit us online at

SOURCE The Roskamp Institute
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
2. Sports Legacy Institute Announces Findings of Forensic Examinations on Wrestler Chris Benoits Brain
3. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
4. Spine Institute of Louisiana Offers Cervical Spine Motion Preservation as an Alternative to Fusion Surgery
5. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
6. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
7. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
8. The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Institute Announce Groundbreaking Partnership to Accelerate Drug Approvals
9. American Meat Institute Calls WCRF Panel Recommendations on Meat Consumption Extreme and Unfounded
10. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
11. American Legion Anticipates Institute of Medicine Report on Gulf War Veterans
Post Your Comments:
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from reveals that behind the tendency ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s ... the world, and the most handsome men, look naturally attractive. Plastic surgery should ...
Breaking Medicine News(10 mins):